Why Corvionis
We focus on the stage where life science programs are most likely to fail
Most early-stage life science programs do not fail because the underlying science lacks promise. They fail because the systems required to translate science into clinical value are not effectively connected.
These structural gaps often become visible only when a program enters critical development stages, where the consequences can be costly, time-consuming, and difficult to reverse.
Corvionis GmbH was established to address precisely this challenge. We focus on critical stages in advanced therapy and early clinical development, helping companies reduce development risk, improve decision quality, and move programs toward IND, First-in-Human (FIH), and international clinical development.
We provide more than consulting
We do not only provide strategic recommendations. We support clients at critical development decision points with execution-oriented capabilities grounded in real project experience.
Our capabilities cover:
- Preclinical and translational medicine strategy
- IND support and regulatory pathway planning
- FIH and early clinical development execution
- Clinical operations and trial coordination
- CRO and supply-chain management
- Cross-border development and multi-system alignment
Our team has directly participated in and led:
- Clinical medicine and patient management
- Translational medicine and early-stage R&D
- IND submissions and regulatory communication
- FIH program design and execution
- Clinical operations management
- Cross-border strategy and partnership negotiations
As a result, we understand not only how programs should be designed, but also why they often fail to move forward in practice.
Why companies choose Corvionis
- Direct involvement of the founding team in critical project execution
- Real-world experience in FIH programs and IND support
- Deep understanding of advanced therapy and early clinical development systems
- Familiarity with regulatory environments in Europe, China, the United States, and Australia
- Access to hospital, KOL, CRO, and industry collaboration networks
- Ability to identify and reduce development and execution risks
- Strength in cross-system coordination and complex stakeholder management
- Founder-led team combining clinical-regulatory expertise with global strategic and commercial execution
Founding team
Corvionis is built on the complementary strengths of its founding team. The company combines clinical-regulatory development leadership with global strategic and commercial execution, creating an integrated cross-system execution capability for complex life science programs.
Dr. Qin Liu
Co-founder
Physician-scientist and biotech executive with more than 20 years of international experience across clinical medicine, translational science, regenerative medicine, and advanced therapy development.
She has extensive early clinical development experience in advanced therapies and has led multiple First-in-Human (FIH) programs to successful regulatory approval. She brings deep practical expertise in IND support, clinical study design, and execution risk management.
Her previous roles include clinical physician, university professor, director of a regenerative medicine research institute, and executive medical director. She has managed large international research programs and advanced multiple translational medicine projects from basic research into clinical development.
Core responsibilities
- Translational and clinical development strategy
- IND and regulatory pathway planning
- FIH program design and execution
- Clinical operations and trial coordination
- KOL, hospital, and CRO network coordination
Luming Xiong
Founder & CEO
Senior international business and strategy executive with more than 30 years of cross-border commercialization and industry experience, focused on global strategy, capital alignment, and commercialization execution.
He previously held senior management roles at IBM and Hella, where he led large-scale international project execution and regional business management. He brings deep experience in cross-border operations and technology-driven business transformation. He has supported companies in accessing NASDAQ capital-market pathways and has been involved in the early incubation and international expansion of multiple technology companies, several of which achieved successful listings and commercial exits.
In life sciences, he focuses on early-stage project identification, strategic incubation, and cross-border commercialization, supporting innovative programs in progressing toward FIH development, technology licensing, and industrial implementation.
Core responsibilities
- Global strategy and cross-border execution
- Commercialization and market expansion
- Strategic partnerships and licensing
- Industry and capital alignment
- International collaboration and negotiation
Our belief
Success in life sciences is not determined by a single scientific breakthrough alone. It depends on whether science, regulation, clinical development, and commercialization can operate as a coherent execution system.
What truly causes failure is often the structural gap between systems, not the science itself.
The mission of Corvionis GmbH is to help innovative programs cross these gaps and build truly executable global development pathways.